By I. Glenn Cohen Over at Jotwell, Michael Carroll (American) has a very nice review of a new paper that is a collaboration between two of our former fellows at the Petrie-Flom Center, Michael Frakes…
Wednesday, October 24, 2012 12:00-1:30pm Wasserstein Hall 3019 Harvard Law School In 2008, the NIH Public Access Policy entered into force, requiring “that all investigators funded by the NIH submit or have submitted for them…
By The Petrie-Flom Center Check out this great summary piece in the Harvard Gazette discussing Glenn Cohen‘s work on medical tourism, including some audio of his recent lecture at the Radcliffe Institute.
By Scott Burris It’s hard to believe that after all these years, all the evidence, and all the reductions in HIV among injection drug users, we still only have 15 states that explicitly authorize syringe…
By Vickie J. Williams I am back after a brief hiatus for the Jewish holidays. L’Shanah Tova to all my readers who have just celebrated the Jewish New Year. The first Monday in October is, of…
By The Petrie-Flom Center Congrats to our blogger, Al Roth, for his Nobel Prize in economics (alongside Lloyd S. Shapley of UCLA)! Al built on Shapley’s theories about the best ways to match “agents” in markets —…
By The Petrie-Flom Center Liberty Mutual Research Institute/Harvard School of Public Health + Univ. of Massachusetts – Health Services Research Postdoctoral Fellowship and Research Scientist Positions HEALTH SERVICES RESEARCH POSTDOCTORAL FELLOWSHIP: The Center for Disability Research…
By Rebecca Haffajee Sure enough, last Friday the American Beverage Association and others, represented by Latham & Watkins, sued to block Mayor Bloomberg’s ban on the sale of sugar-sweetened beverages larger than 16 oz at…
By Suzanne M. Rivera, Ph.D. By now, many people have seen a still photo or video footage of Rep. Paul Broun (R-Georgia), standing in front of a wall full of deer heads, proclaiming that evolution,…
By Leslie P. Francis In 2007, motivated by concerns that pharmaceutical companies were not sharing negative data about what had been learned in clinical trials, Congress established enhanced reporting requirements. A series of articles published…
